Orexigen Therapeutics, Inc.
OREX
NASDAQ0.22
USD
-0.02
- -
CIK
0001382911
Return %
Stock
S&P500
1Y
- -
26.99
3Y
- -
77.19
5Y
- -
79.08
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- IPO Date
- Apr 26, 2007
- CIK
- 0001382911
- Similar Companies
- Business
- Orexigen Therapeutics, Inc. (OREX) develops and commercializes pharmaceutical products for the treatment of obesity and related metabolic disorders. The company focuses on therapies targeting the central nervous system to promote weight loss and maintenance, including its lead product Contrave (naltrexone HCl/bupropion HCl extended-release tablets), an FDA-approved combination medication for chronic weight management in adults with obesity or overweight conditions accompanied by weight-related comorbidities; and Mysimba, the European brand name for Contrave marketed for similar indications. Its pipeline historically included investigational candidates such as empatic (bupropion HCl/zonisamide), though commercialization efforts centered on Contrave following regulatory approvals in 2014. Founded in 1999 and headquartered in San Diego, California, Orexigen operates primarily in the biopharmaceutical industry, with products distributed in the United States through partnerships and in Europe via Takeda Pharmaceuticals. The company targets healthcare providers, obesity clinics, and patients seeking pharmacotherapy options alongside diet and exercise, with geographic operations spanning North America and select European markets. It maintains a lean structure without notable subsidiaries, previously listed on NASDAQ under OREX prior to its exit from public trading. In recent major developments, Orexigen underwent a Chapter 11 bankruptcy reorganization in 2018, emerging as a private entity focused on Contrave commercialization; this was followed by the acquisition of its assets by Nalpropion Pharmaceuticals in 2019, marking a significant strategic shift to streamline operations and enhance market access for Contrave. In 2021, Nalpropion (formerly Orexigen) announced expanded distribution partnerships, including with Currax Pharmaceuticals, which assumed full rights to Contrave in 2022 to bolster sales amid post-pandemic obesity treatment demand. These changes reflect ongoing efforts to optimize funding and partnerships for sustained growth in the anti-obesity sector.